Form 4: Ocuphire Pharma Director Richard J. Rodgers Reports Acquisition and Disposal of Common Stock

Director Richard J. Rodgers reports acquisition of 41,143 shares of common stock and disposal of 239,151 shares, along with stock option grant.

Summary

• Richard J. Rodgers, a director of Ocuphire Pharma, Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• On June 11, 2024, Rodgers acquired 41,143 shares of common stock.
• On the same day, Rodgers disposed of 239,151 shares of common stock.
• Following these transactions, Rodgers beneficially owns 239,151 shares of common stock.
• Rodgers was also granted a stock option to buy 35,181 shares of common stock at an exercise price of $1.72, which vests on the earlier of June 11, 2025, or the day prior to the company's next annual meeting of stockholders after the grant date.
• Amy Rabourn, acting as attorney-in-fact, signed the report on behalf of Richard J. Rodgers on June 13, 2024.
• Rodgers also has a Power of Attorney designating Amy Rabourn and Sharon Goldbach to act on his behalf for SEC filings.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. The disposal of shares could be seen as slightly negative, but the grant of stock options is a positive incentive.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders.

Negatives

• The disposal of 239,151 shares by a director could be perceived negatively by investors.

Risks

• The vesting of the restricted stock units and stock options is contingent upon the director's continued service, which introduces a retention risk.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon the director's continued service, which introduces a retention risk.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Similar filings are common across publicly traded companies, such as Regeneron Pharmaceuticals Inc. and Alnylam Pharmaceuticals, Inc., where directors and officers regularly report transactions in company stock.
• The size and frequency of these transactions can vary widely depending on the company's compensation policies and the individual's investment strategies.

Stakeholder Impact

• The transactions reported in the Form 4 provide transparency to shareholders regarding the director's holdings and incentives.
• Employees may be indirectly affected by the director's actions, as they can influence the company's performance and stock price.

Key Dates